Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-(2-oxo)pentadecylcoa is a synthetic small molecule derivative of coenzyme A featuring a long-chain fatty acid (specifically a 2-oxopentadecyl group) attached via a thioester bond. It is classified as an S-alkyl-CoA and functions primarily as an experimental biochemical tool. This compound acts as a nonhydrolyzable analog of myristoyl-CoA and serves as a potent inhibitor of myristoyl-CoA:protein N-myristoyltransferase (NMT), the enzyme responsible for transferring myristoyl groups to the N-terminal glycine residue of target proteins[3][5]. By inhibiting NMT, it disrupts protein myristoylation—a modification essential for membrane localization and function of various signaling proteins. Its main applications are in biochemical research on lipid metabolism, protein modification pathways (notably myristoylation), and antifungal drug development targeting NMT[3][9]. There are no approved therapeutic indications or clinical trials for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-(2-oxo)pentadecylcoa.